HMGCR and cardiovascular disorder: Most MASLD patients have a 64% risk of cardiovascular disease, and, thus, inhibiting HMGCR can be of particular interest for therapeutic purposes due to reduced free cholesterol levels in the blood, decreased risk for atherosclerotic plaques, and anti-hypertrophic effects [39].